E2 Raises $80 Million to Advance Thrombectomy Platform for Pulmonary Embolism

Funding will support commercialization of E2's novel Hēlo® Thrombectomy Platform to treat life-threatening blood clots.

Apr. 7, 2026 at 2:33pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate internal structure of a medical device used to treat pulmonary embolism, with glowing, ethereal lines against a dark background.E2's innovative Hēlo® Thrombectomy Platform aims to redefine the standard of care for removing dangerous blood clots and treating life-threatening pulmonary embolism.Menlo Park Today

Endovascular Engineering, Inc. (E2), a medical technology company focused on venous thromboembolism (VTE) treatment, has raised an $80 million Series C financing co-led by Gilde Healthcare and Norwest. The funding will support commercialization of E2's Hēlo® Thrombectomy Platform, a novel system designed to improve outcomes and efficiency in removing dangerous blood clots, particularly for pulmonary embolism - a leading cause of cardiovascular death.

Why it matters

Pulmonary embolism is a complex and often life-threatening condition, and there remains a need for more effective procedural solutions to remove dangerous blood clots. E2's technology aims to advance the standard of care for VTE treatment and address unmet needs in the thrombectomy market.

The details

The Hēlo® Platform features a patented dual-action mechanism that integrates aspiration with mechanical clot disruption, enabling efficient single-pass procedures through a small-profile catheter. E2 believes its integrated platform can support procedural efficiency and clinical performance as adoption of mechanical thrombectomy continues to expand.

  • The $80 million Series C financing was announced on April 7, 2026.

The players

Endovascular Engineering, Inc. (E2)

A commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE).

Gilde Healthcare

A co-lead investor in E2's $80 million Series C financing round.

Norwest

A co-lead investor in E2's $80 million Series C financing round.

Dan Rose

Chief executive officer at E2.

Geoff Pardo

General partner at Gilde Healthcare, who will join the E2 Board.

Zack Scott, M.D.

General partner at Norwest, who will join the E2 Board.

Got photos? Submit your photos here. ›

What they’re saying

“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the VTE space. We are incredibly proud of the capabilities of the Hēlo® Platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.”

— Dan Rose, Chief executive officer at E2

“E2 represents the type of innovation we look for - technology that meaningfully advances clinical care and has the potential to define a category. We believe the Hēlo® Platform addresses unmet needs in thrombectomy and are excited to support E2 as they scale toward commercialization and broader clinical impact.”

— Geoff Pardo, General partner at Gilde Healthcare

“Pulmonary embolism is a complex and often life-threatening condition, and there remains a need for more effective procedural solutions. We are impressed by E2's leadership team and their thoughtful approach to building a scalable commercial organization. E2's technology will become the platform of choice for treating pulmonary embolism with mechanical thrombectomy, and we look forward to supporting their next phase of growth.”

— Zack Scott, M.D., General partner at Norwest

What’s next

E2 plans to use the $80 million in Series C funding to build a strong commercial organization and continue important investments in R&D and operations to support the commercialization of its Hēlo® Thrombectomy Platform.

The takeaway

E2's novel Hēlo® Thrombectomy Platform represents a significant advancement in the treatment of pulmonary embolism, a life-threatening condition. The $80 million in Series C funding will enable the company to scale its commercial operations and drive broader clinical impact with its innovative technology.